Remnant cholesterol, but not low‐density lipoprotein cholesterol, is associated with intra‐pancreatic fat deposition

Aim To investigate the associations of components of the lipid panel (and its derivatives) with intra‐pancreatic fat deposition (IPFD). Methods All participants underwent abdominal magnetic resonance imaging on the same 3.0‐Tesla scanner and IPFD was quantified. Blood samples were collected in the f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes, obesity & metabolism obesity & metabolism, 2023-11, Vol.25 (11), p.3337-3346
Hauptverfasser: Skudder‐Hill, Loren, Sequeira‐Bisson, Ivana R., Ko, Juyeon, Cho, Jaelim, Poppitt, Sally D., Petrov, Maxim S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim To investigate the associations of components of the lipid panel (and its derivatives) with intra‐pancreatic fat deposition (IPFD). Methods All participants underwent abdominal magnetic resonance imaging on the same 3.0‐Tesla scanner and IPFD was quantified. Blood samples were collected in the fasted state for analysis of lipid panel components. A series of linear regression analyses was conducted, adjusting for age, sex, ethnicity, body mass index, fasting plasma glucose, homeostatic model assessment of insulin resistance, and liver fat deposition. Results A total of 348 participants were included. Remnant cholesterol (P = 0.010) and triglyceride levels (P = 0.008) were positively, and high‐density lipoprotein cholesterol level (P = 0.001) was negatively, associated with total IPFD in the most adjusted model. Low‐density lipoprotein cholesterol and total cholesterol were not significantly associated with total IPFD. Of the lipid panel components investigated, remnant cholesterol explained the greatest proportion (9.9%) of the variance in total IPFD. Conclusion Components of the lipid panel have different associations with IPFD. This may open up new opportunities for improving outcomes in people at high risk for cardiovascular diseases (who have normal low‐density lipoprotein cholesterol) by reducing IPFD.
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.15233